Search
Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigationalA safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800] … [A34604] This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities.
Categories: Adrenergic alpha-1 Receptor Antagonists, P-glycoprotein inhibitorsSynonyms: N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideFluocortolone
go.drugbank.com/drugs/DB08971ApprovedWithdrawnFluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Corticosteroids for Systemic Use, PlainTAK-428
go.drugbank.com/drugs/DB05499ExperimentalTAK-428 is a drug for treating diabetic neuropathy. … It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.
Zafirlukast
go.drugbank.com/drugs/DB00549ApprovedZafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. … Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.
Categories: Drugs for Obstructive Airway Diseases, Cytochrome P-450 SubstratesSparteine
go.drugbank.com/drugs/DB06727ApprovedWithdrawnSparteine is a plant alkaloid derived from _Cytisus scoparius_ and _Lupinus mutabilis_ which may chelate calcium and magnesium. … Sparteine is not currently FDA-approved for human use, and its salt, sparteine sulfate, is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsCobalt
go.drugbank.com/drugs/DB14574ApprovedWithdrawnExcept for radioactive forms of cobalt and cobalamin, the FDA withdrew its approval for the use of drug products containing cobalt salts.[L43942] … Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use.[L48011]
Categories: Antidepressive Agents Indicated for Depression, P-glycoprotein substratesEtripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigational[A275243, A275248] The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesMolindone
go.drugbank.com/drugs/DB01618ApprovedMolindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. … It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors.
Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor AntagonistsCNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.